STUDY 31/A5349 POPULATION PHARMACOKINETIC ANALYSIS OF RIFAPENTINE AND MOXIFLOXACIN
Study 31/A5349 (NCT02410772) was a phase 3 randomized controlled trial that demonstrated noninferiority of a 4-month isoniazid, rifapentine (RPT), and pyrazinamide plus moxifloxacin (MXF) regimen compared to the 6-month standard treatment for drug-sensitive tuberculosis (TB). RPT is well known for its variability in drug exposures and is also an enzyme inducer, inducing not only its…